Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29418661 | 1.00 | TSHR (0.42) | TSHRSLC6A2TAAR1LMNAPDE4D | |
| SCHEMBL30444100 | 1.00 | TSHR (0.42) | TSHRSLC6A2TAAR1LMNAPDE4D | |
| SCHEMBL15538748 | 1.00 | TSHR (0.42) | TSHRSLC6A2TAAR1LMNAPDE4D | |
| SCHEMBL9048533 | 0.87 | HTR2A (0.43) | TSHRSLC6A2TAAR1LMNAHTR2A | |
| SCHEMBL29015102 | 0.81 | TAAR1 (0.37) | TSHRSLC6A2TAAR1LMNAHTR2A | |
| SCHEMBL15551716 | 0.81 | TAAR1 (0.37) | TSHRSLC6A2TAAR1LMNAHTR2A | |
| SCHEMBL29418820 | 0.81 | TAAR1 (0.37) | TSHRSLC6A2TAAR1LMNAHTR2A | |
| SCHEMBL17119535 | 0.81 | TAAR1 (0.37) | TSHRSLC6A2TAAR1LMNAHTR2A | |
| SCHEMBL17093315 | 0.81 | TAAR1 (0.37) | TSHRSLC6A2TAAR1LMNAHTR2A | |
| SCHEMBL29418611 | 0.81 | TAAR1 (0.37) | TSHRSLC6A2TAAR1LMNAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-02-13 | — | — | US | disclosed |
| EP-4211125-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| WO-2022054987-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-03-17 | — | — | WO | disclosed |
| EP-3443959-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-02-20 | — | — | EP | disclosed |
| EP-3079685-B1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-11-28 | — | — | EP | disclosed |
| EP-3079686-B1 | SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-10-24 | — | — | EP | disclosed |
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| EP-3079685-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | Bio-Pharm Solutions Co., Ltd. (KR) | 2016-10-19 | — | — | EP | disclosed |
| EP-3079686-A1 | SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY | Bio-Pharm Solutions Co., Ltd. (KR) | 2016-10-19 | — | — | EP | disclosed |
| US-9221783-B2 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-9221783-B2 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-09-24 | — | — | US | disclosed |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-09-24 | — | — | US | disclosed |
| WO-2015088273-A9 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS, CO., LTD. (KR) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015088273-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS, CO., LTD. (KR) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015088271-A1 | SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY | BIO-PHARM SOLUTIONS, CO., LTD. (KR) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | SLC6A4, SLC6A3, SLC6A2 | TSHR 2322/4885SLC6A2 3/4885TAAR1 379/4885 |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | MYLK, MUSK, MYLK2 | TSHR 2872/4885SLC6A2 462/4885TAAR1 1952/4885 |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | STS, SULT2A1, GRIK5 | TSHR 4659/4885SLC6A2 271/4885TAAR1 4198/4885 |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | SLC6A4, SLC6A3, SLC6A2 | TSHR 2322/4885SLC6A2 3/4885TAAR1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.